MBX Biosciences
79 hedge funds and large institutions have $263M invested in MBX Biosciences in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
25% more funds holding
Funds holding: 63 → 79 (+16)
8.15% more ownership
Funds ownership: 98.57% → 106.72% (+8.2%)
57% less capital invested
Capital invested by funds: $606M → $263M (-$343M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$12M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$2.84M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.64M |
| 4 |
JP Morgan Chase
New York
|
+$2.03M |
| 5 |
O
OrbiMed
New York
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.06M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.22M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.87M |
| 4 |
Millennium Management
New York
|
-$1.73M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$641K |
MBX Hedge Fund Activity: Q1 2025 in Review
79 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q1 2025, worth a combined $263M — down 57% from $606M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MBX positions and 10 closed out — a net gain of 16 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.06M sold.
- 79 institutional investors held MBX Biosciences (MBX) as of Q1 2025, up from 63 in Q4 2024.
- Funds reported $263M of MBX Biosciences stock for Q1 2025, down 57% quarter-over-quarter.
- 26 funds opened new MBX Biosciences positions in Q1 2025 and 10 closed out, a net change of +16 holders.
- The largest MBX Biosciences buyer in Q1 2025 was MPM BioImpact, an estimated $12M added.
- The largest MBX Biosciences seller in Q1 2025 was Citadel Advisors, an estimated $4.06M sold.
Based on aggregated 13F filings for Q1 2025.